CDC Website CDC Website

To Join the NPIN community or

You are here

Federal Government Agencies

Adipogenesis, Adipocyte Function and Obesity Following HIV Infection, Antiretroviral Therapy, or Pre-Exposure Prophylaxis (R01 Clinical Trial Optional)

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that there are unique mechanisms contributing to the development of obesity in PWH versus people without HIV. Furthermore, the biology of the adipocytes might be altered in overweight or obese PWH versus overweight or obese people without HIV.

HIV/AIDS Clinical Trials Units (UM1 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Clinical Trials Units (CTUs) to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. 

Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (U01 Clinical Trial Not Allowed)

The objective of this Funding Opportunity Announcement (FOA) is to support the evaluation of early stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical diagnostic algorithms in TB endemic countries. Evaluation studies should focus on: 1) proof-of principle studies of novel diagnostic tests and strategies and 2) provide feedback to diagnostic developers on the performance of the technology and most effective strategy for use of a diagnostic technology in an endemic setting. 
 

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: CNS Data Generation (UM1 Clinical Trial Not Allowed)

To support generation of single cell datasets for one or more brain regions relevant to opioid use disorder and persistent HIV infection. If fully successful, this project will generate 1. A cellular parts list for selected NIDA-relevant brain regions, 2. Reveal how cell types within these brain regions differ from one another with respect to gene expression, 3. Reveal how cell types within these brain regions are altered by chronic opioid exposure providing potential novel therapeutic targets for opioid addiction, 4.

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)

Along with RFA-DA-19-037, which will support the generation of single cell datasets for one or more brain regions relevant to opioid use disorder and persistent HIV infection, a data coordination/analysis/outreach center (RFA-DA-19-038) will be established to make NIDA-funded single cell data and other molecular HIV/SUD data FAIR (Findable, Accessible, Interoperable, and Reusable). Harmonized single cell HIV/SUD data sets will enable immediate data mining by the scientific community for HIV and/or SUD biomarkers and potential pathways for therapeutic intervention.

Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional)

The objective of this FOA is to advance non-sputum-based tuberculosis (TB) diagnostics for use in HIV-1 infected and HIV-1 exposed uninfected children (HEU) for improved, simplified, rapid and decentralized diagnosis of TB disease. This opportunity will support discovery and validation of novel biomarkers useful for TB diagnosis or the development/optimization and early validation of novel TB diagnostic technologies. 

Subscribe to RSS - Federal Government Agencies